



Notification HUM-6876, HUM-6878; HUM; 6880; HUM-6882; HUM-6884; HUM-6886; HUM-6888; HUM-6890; HUM-6892; HUM-6894:

Category

HCPCS - Drugs & Biologicals

Topic

Fam-trastuzumab deruxtecan – HCPCS code J9358

What is changing? / Change Description:

<u>HUM-ID</u>	<u>Topic</u>	<u>Change Description</u>
<u>6876</u>	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>We limit reimbursement of charges for HCPCS code J9358 to claims submitted with any of the following diagnoses:• Breast cancer• HER2-overexpressing esophagogastric junction cancer• HER2-overexpressing gastric cancer• HER2-overexpressing non-small cell lung cancer• Brain metastases in HER2-overexpressing breast cancer• HER2-overexpressing colorectal cancer• HER2-overexpressing esophageal cancer</u>
<u>6878</u>	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>If billed with a diagnosis of personal history of malignant neoplasm, we do not reimburse charges of HCPCS code J9358 unless a secondary malignancy diagnosis is also present on the claim. Additionally, if billed with a diagnosis of a secondary malignancy, we do not reimburse charges of HCPCS code J9358 unless a diagnosis of primary malignancy or personal history of malignant neoplasm is also present on the claim.</u>
<u>6880</u>	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>For a diagnosis of brain metastases in HER2-overexpressing breast cancer or breast cancer, we apply the following limitations for charges of HCPCS code J9358:• No more than 675 units per date of service for provider specialties other than home infusion therapy or pharmacy• No more than 1,350 units per 6 weeks for a provider specialty other than pharmacy• No more than 1,400 units per 6 weeks for provider specialty of pharmacy</u>
<u>6882</u>	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>For a provider specialty other than home infusion therapy or pharmacy, we limit reimbursement of charges for HCPCS code J9358 to no more than 800 units per date of service if the diagnosis is any of the following:• HER2-overexpressing colorectal cancer• HER2-overexpressing esophageal cancer• HER2-overexpressing esophagogastric junction cancer• HER2-overexpressing gastric cancer• HER2-overexpressing non-small cell lung cancer</u>

6884	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>We limit reimbursement of charges for HCPCS code J9358 to no more than 1 administration every 3 weeks and no more than 1,600 units per 6 weeks for any of the following diagnoses:• HER2-overexpressing colorectal cancer• HER2-overexpressing esophageal cancer• HER2-overexpressing esophagogastric junction cancer• HER2-overexpressing gastric cancer• HER2-overexpressing non-small cell lung cancer</u>
6886	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>We do not reimburse charges for HCPCS code J9358 for patients younger than 18 if billed with any of the following diagnoses:• Breast cancer• HER2-overexpressing esophagogastric junction cancer• HER2-overexpressing gastric cancer• HER2-overexpressing non-small cell lung cancer• Brain metastases in HER2-overexpressing breast cancer• HER2-overexpressing colorectal cancer• HER2-overexpressing esophageal cancer</u>
6888	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>We limit reimbursement for charges of administration of HCPCS code J9358 to intravenous infusion only.</u>
6890	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>We do not reimburse charges for HCPCS code J9358 if a charge for a trastuzumab or its biosimilars has been billed for the same date of service.</u>
6892	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>If billed with a diagnosis of HER2-overexpressing colorectal cancer, HER2-overexpressing esophageal cancer, HER2-overexpressing esophagogastric junction cancer, HER2-overexpressing gastric cancer or HER2-overexpressing non-small cell lung cancer, we do not reimburse charges of HCPCS code J9358 unless either of the following:• HER2 testing has been billed in the patient's lifetime• Pertuzumab, pertuzumab trastuzumab hyaluronidase, margetuximab, ado-trastuzumab emtansine, trastuzumab, trastuzumab hyaluronidase or fam-trastuzumab deruxtecan has not been billed within the past year</u>



6894	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>We limit reimbursement of HCPCS code J9358 to no more than 99 units if submitted with modifier JW (drug amount discarded/not administered to any patient).</u>
------	--	---

Language

English

Impacted Products

Medicaid – Louisiana

Why is Humana making this change? / Change Reason:

<u>HUM-ID</u>	<u>Topic</u>	<u>Change Reason</u>
6876	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia.</u>
6878	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>The limitations listed above are supported by ICD-10-CM coding guidelines.</u>
6880	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia.</u>

Humana

Healthy Horizons®
in Louisiana

6882	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia.</u>
6884	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia.</u>
6886	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>According to the FDA-approved package insert and prescribing information and pharmaceutical compendia, the safety and effectiveness of HCPCS code J9358 has not been established in pediatric patients.</u>
6888	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>According to the FDA-approved package insert and prescribing information and pharmaceutical compendia, HCPCS code J9358 is administered by intravenous infusion only. Do not administer as push or bolus injections.</u>
6890	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>According to the FDA-approved package insert and prescribing information and pharmaceutical compendia, fam-trastuzumab deruxtecan should not be substituted for or with trastuzumab or ado- trastuzumab emtansine.</u>

Humana

Healthy Horizons®
in Louisiana

6892	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>According to the FDA-approved package insert and prescribing information and pharmaceutical compendia, the patient should have previously tested HER2 positive or had a previous trastuzumab-based therapy.</u>
6894	<u>Fam-trastuzumab deruxtecan – HCPCS code J9358</u>	<u>According to the FDA-approved package insert and prescribing information for HCPCS code J9358 and guidance from state Medicaid agencies, it is inappropriate to bill wastage equal to or in excess of the smallest vial size of a drug or biological agent. Note: For additional information, refer to the Humana claims payment policies and search keyword “JW Modifier.”</u>